AbbVie's Early Parkinson's Candidate Hits Primary Goal In Pivotal Late-Stage Study

On Monday, AbbVie Inc. (NYSE:ABBV) revealed topline results from its pivotal Phase 3 TEMPO-2 trial, which evaluated investigational tavapadon as a flexible-dose monotherapy in early Parkinson's disease.

Tavapadon is the first and only D1/D5 partial agonist under investigation as a once-daily treatment for Parkinson's disease.

The TEMPO-2 trial evaluated the efficacy, safety and tolerability of a flexible-dose (5 mg to 15 mg, once daily) treatment with tavapadon as a monotherapy in adults with early Parkinson's disease.

Also Read: Alector/AbbVie-Partnered Alzheimer's Drug Disappoints In Mid-Stage Study; Alector Lays Off 17% Of Workforce

The trial met its primary endpoint – patients treated with tavapadon experienced a statistically significant ...

Full story available on Benzinga.com